Onpattro
Approval
- What happened
The FDA approved Onpattro, a first-of-its-kind RNA-based medicine, for nerve damage caused by hereditary ATTR amyloidosis in adults.
- Why it matters
By cutting the faulty protein, it can reduce the deposits that build up in nerves, improving symptoms.
BioPharm International, 13 Aug 2018- How far from your life
Approved or on sale
Patisiran (Onpattro) is on step 4 of 5. You can get it now, though it may not be common yet.
- Source
“a first-of-its-kind RNA-based therapy for treating peripheral nerve disease (polyneuropathy)”BioPharm International, 13 Aug 2018
The bigger picture
More on Onpattro
On step 4 of 5: Approved or on sale. Everything we track on it